SI — Shoulder Innovations, Inc.

Is SI overbought or oversold? Here is the current MarketMoodz read.

Health Care · Health Care

Neutral As of November 17, 2026

Shoulder Innovations, Inc. (SI) currently reads Neutral on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Health Care name (Health Care) last closed at $20.45. The rating moved from Overbought to Neutral on November 14, 2026.

AI analysis

Shoulder Innovations, Inc. (SI) is a niche medical-device issuer whose near-term outlook is governed by adoption of device procedures, commercial execution and reimbursement clarity. Market conditions during the recent window were cautious, leaving limited broad upside for small-cap healthcare names; absent fresh filings or social commentary there is elevated uncertainty. Key upside triggers would be clear clinical/commercial milestones or favorable reimbursement/newsflow; downside stems from execution, regulatory/reimbursement setbacks and supply-chain pressures.

Key factors

  • Niche positioning as a medical device company focused on shoulder solutions — potential to benefit from procedure volumes and targeted commercial adoption
  • Market environment over the last four hours is cautious with defensive positioning, which could limit near-term upside for small-cap healthcare names
  • Limited available public filings and social/research commentary in the provided window, increasing uncertainty around near-term fundamentals
  • Sector tone is neutral-to-slightly-positive for health care, which provides a stable backdrop but not a strong tailwind
  • Potential product or procedural adoption catalysts (new product launches, distributor deals, or CMS/reimbursement updates) could drive upside if announced
  • Supply-chain and equipment-manufacturer commentary in the sector suggests continued margin pressure risk for device makers

Risks

  • Scarcity of recent EDGAR filings and public financial detail in the provided data set, limiting visibility into revenue, margins and cash runway
  • Regulatory and reimbursement uncertainty for device procedures that can materially affect adoption and pricing
  • Competition from larger, better-capitalized orthopedic and arthroscopy device manufacturers
  • Operative and supply-chain disruptions that can constrain device availability or increase costs
  • Low liquidity / small-cap volatility that can amplify price moves in a risk-off market environment
  • Execution risk on commercialization (sales force effectiveness, distributor relationships, and procedural training)

See today's live rating, score and targets

Members see the live hourly rating for SI — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.